Eminence Capital LP Has $115.83 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Eminence Capital LP reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 37.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 627,472 shares of the medical research company's stock after selling 376,000 shares during the quarter. Charles River Laboratories International accounts for approximately 1.8% of Eminence Capital LP's portfolio, making the stock its 29th largest holding. Eminence Capital LP owned 1.23% of Charles River Laboratories International worth $115,831,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its position in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after buying an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Optiver Holding B.V. acquired a new position in Charles River Laboratories International in the 4th quarter valued at about $37,000. GeoWealth Management LLC lifted its holdings in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares in the last quarter. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International in the 4th quarter valued at about $48,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares of the company's stock, valued at $30,302,271.39. This trade represents a 3.42% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company's stock, valued at $3,252,112.50. The trade was a 18.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price objective for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Barclays increased their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research note on Thursday. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research report on Monday, March 3rd. Robert W. Baird increased their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday. Finally, Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their price target for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $176.00.

Charles River Laboratories International Stock Up 3.9%

CRL stock traded up $5.45 during mid-day trading on Monday, hitting $144.24. 979,497 shares of the company were exchanged, compared to its average volume of 967,149. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $7.08 billion, a PE ratio of 961.49, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The firm has a fifty day simple moving average of $138.40 and a 200 day simple moving average of $166.20.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business's revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $2.27 earnings per share. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).